Amgen Inc.

Amgen Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen specializes in treatments for serious illnesses such as cancer, cardiovascular disease, bone health, inflammation, and nephrology. The company's portfolio includes well-known biologic drugs like Enbrel, Neulasta, and Prolia, as well as newer therapies like Repatha and LUMAKRAS. Amgen also has a growing biosimilars business, offering lower-cost alternatives to expensive biologic drugs.

Amgen generates revenue primarily through the sale of prescription drugs, with a diversified product portfolio spanning multiple therapeutic areas. The company's top-selling products include Prolia (for osteoporosis), Repatha (for high cholesterol), and Otezla (for psoriasis). Amgen also earns royalties from licensing agreements and collaborates with other biotech firms to expand its pipeline. The company invests heavily in R&D, spending over $4 billion annually to develop new drugs and biosimilars. Manufacturing is done in-house at facilities in the U.S., Europe, and Asia.

Amgen operates in the highly competitive biotechnology and pharmaceutical industry, competing with large players like Pfizer, Merck, and AbbVie, as well as specialized biotech firms. The company's competitive advantages include a strong pipeline of innovative therapies, a robust biosimilars portfolio, and a global sales and marketing infrastructure. Amgen's focus on high-value therapeutic areas such as oncology and cardiovascular disease positions it well for long-term growth, though it faces challenges from patent expirations and pricing pressures.

Amgen's customers are primarily healthcare providers, including hospitals, clinics, and physicians, as well as patients with chronic or serious conditions. The company's drugs are prescribed by specialists such as oncologists, rheumatologists, and cardiologists. Geographically, Amgen's largest market is the United States, which accounts for about 80% of its revenue. The remaining revenue comes from international markets, with significant presence in Europe, Canada, and Japan. Amgen also has a growing footprint in emerging markets like China and Brazil.

An auto-generated descriptive profile based on company data, for informational purposes only.